Alantra advises Prescient Healthcare Group on investment from Bridgepoint Development Capital



Jan 2021
Sell-side advisory

Alantra, the independent global mid-market investment banking firm, has advised the shareholders of Prescient Healthcare Group (Prescient), a global product strategy advisory firm serving the pharmaceutical and biotech industries, on an investment by Bridgepoint Development Capital, replacing current investor Baird Capital as the majority shareholder.

Founded in 2007, Prescient is headquartered in London and has offices in the US, India and China. The business provides product strategy services to help its clients make better clinical and commercial decisions, resulting in enhanced outcomes for patients. Prescient works with many of the leading multinational pharmaceutical companies, as well as a growing number of emerging biotech and specialty pharmaceutical organizations. Prescient has formed a partnership with Bridgepoint to support the continued scaling of its talent platform, client value proposition and global infrastructure.

Alantra’s Healthcare team have known Prescient for many years. They were appointed due to their significant experience of working with pharma services businesses and record of identifying strategic partners and delivering investment solutions. Their role encompassed advising the shareholders on the options available to support the next stage of Prescient’s growth, designing the deal process, identifying and educating potential partners and supporting the team to enable an efficient process through to completion. 

Anthony Harrington and Tom Cowap, partner and director at Alantra, led the deal supported by vice president Ollie Hickley and associate Matthew Kumeta.​

Anthony Harrington, partner at Alantra, commented, “The Prescient team have built a world-class insight and intelligence business in the pharma services sector. They have developed a distinctive, tech-enabled solution which combines data and analytics with strategic insights and advisory; they have successfully implemented a multi-national growth strategy; and they have proved adept at attracting talented employees. The team are poised to continue to deliver strong growth into the future and they have chosen an excellent partner to assist them in Bridgepoint Development Capital.”

Tom Cowap, director at Alantra, added, “This is Alantra’s fourteenth deal in the pharma services sector in the last 12 months, all of which have involved significant private equity interest. Private equity investment is an attractive strategic option for many management teams in the sector and we will continue to see significant interest and competition for high quality businesses like Prescient.”

“We are thrilled to be partnering with Bridgepoint, which has an impressive track record supporting the scaling of people-based businesses. Bridgepoint buys into our mission of becoming the biopharma strategy partner most respected for its people, expertise and impact,” said Jamie Denison-Pender, Prescient CEO. “I’m excited by the collaborative approach and hunger for excellence that Bridgepoint will bring to the boardroom and much look forward to our partnership as we continue to invest in our passion for helping our amazing clients develop and commercialize innovative treatments that bring such hope and relief to patients globally.”

Squire Patton Boggs (Mark Yeo) was the legal advisor to Prescient Healthcare Group’s shareholders.

Related Transactions